Selected article for: "control cell and ebov infection"
Author: Bethany Brunton; Kai Rogers; Elisabeth K. Phillips; Rachel B. Brouillette; Ruayda Bouls; Noah S. Butler; Wendy Maury
Title: TIM-1 Serves as a Nonredundant Receptor for Ebola Virus, Enhancing Viremia and Pathogenesis
  • Document date: 2018_11_8
    • ID: mbctin6l_6
    Snippet: As observed for the T cell-competent mice in above studies, T cell-depleted control mice 368 challenged with EBOV GP/rVSV succumbed to the infection between 4-6 days. Likewise, while 369 T cell-depleted TIM-1 -/mice had significantly better survival than T cell depleted control mice 370 they did not exhibit improved survival over TIM-1 -/mice that were not T cell-depleted ( The copyright holder for this preprint (which was not peer-reviewed) is t.....
    Document: As observed for the T cell-competent mice in above studies, T cell-depleted control mice 368 challenged with EBOV GP/rVSV succumbed to the infection between 4-6 days. Likewise, while 369 T cell-depleted TIM-1 -/mice had significantly better survival than T cell depleted control mice 370 they did not exhibit improved survival over TIM-1 -/mice that were not T cell-depleted ( The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. It . https://doi.org/10.1101/466102 doi: bioRxiv preprint identifying TIM-1 expressing cells that serve as viral targets and understanding the contribution 469 of these cells to the EBOV disease pathogenesis, we will be able to better develop TIM-1 470 specific therapeutics against EBOV infection. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. It . https://doi.org/10.1101/466102 doi: bioRxiv preprint C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry. J 508

    Search related documents:
    Co phrase search for related documents
    • control mouse and improve survival: 1, 2
    • disease pathogenesis and ebov infection: 1, 2
    • disease pathogenesis and express cell: 1, 2
    • disease pathogenesis and improve survival: 1
    • disease pathogenesis and specific therapeutic: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • EBOV GP rVSV challenge and filovirus entry: 1
    • ebov infection and express cell: 1
    • ebov infection and filovirus entry: 1, 2
    • express cell and specific therapeutic: 1, 2
    • improve survival and specific therapeutic: 1, 2, 3, 4